Leef Brands (LEEEF) Net Cash Flow (2025 - 2026)
Leef Brands (LEEEF) reported Net Cash Flow of $3.6 million for Q1 2026, up 296.28% on a YoY basis from $899673.1 in Q1 2025, and up 296.28% sequentially from -$1.8 million in Q1 2025.
Leef Brands (LEEEF) Net Cash Flow (2025 - 2026) Analysis & Trends
Leef Brands (LEEEF) has 2 years of Net Cash Flow data on file, last reported at $3.6 million in Q1 2026.
- For the quarter ending Q1 2026, Net Cash Flow rose 296.28% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (changed N/A YoY), and the FY2025 full-year result was -$540914.0, up 85.34% from the prior year.
- Net Cash Flow grew to $3.6 million in Q1 2026, from -$1.8 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $3.6 million in Q1 2026 to a low of -$1.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 202.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -526.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 711.50 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -277.40 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 461.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -446.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -112.00 Mn |
| 10 | Leef Brands | 51.94 Mn | 46.18 Mn | 4.62 Mn | 3.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.57 Mn |
| Mar 31, 2026 | 3.57 Mn |
| Mar 31, 2025 | -1.82 Mn |
| Mar 31, 2025 | -1.82 Mn |